PDF(987 KB)
Association of serum vitamin D level with severity and treatment in children with Henoch-Schönlein purpura
FAN Li, LIU Heng, WANG Yu-Chuan, CHEN Li, ZHOU Jing-Jing, CUI Yu-Xia
Chinese Journal of Contemporary Pediatrics ›› 2017, Vol. 19 ›› Issue (7) : 796-799.
PDF(987 KB)
PDF(987 KB)
Association of serum vitamin D level with severity and treatment in children with Henoch-Schönlein purpura
Objective To investigate the association of serum vitamin D[25-(OH)D3] level with the severity and treatment in children with Henoch-Schönlein purpura (HSP). Methods A total of 50 children with newly-diagnosed HSP between January and December, 2015 were enrolled as HSP group, and 49 healthy children were enrolled as control group. Fasting serum samples were collected, and ELISA was used to measure serum 25-(OH)D3 level. According to the serum 25-(OH)D3 level, the HSP group were further divided into normal group (> 20 ng/mL) (n=9), insuffciency group (15-20 ng/mL) (n=15), defciency group (≤ 15 ng/mL) (n=25), and severe defciency group (≤ 5 ng/mL) (n=1). The general data, clinical manifestations, hormone therapy, course of disease before admission, and length of hospital stay were compared between groups. Results The HSP group had a signifcantly lower serum 25-(OH)D3 level than the control group (16±6 ng/mL vs 29±5 ng/mL; P < 0.01). Compared with the normal and insuffciency groups, the defciency and severe deficiency groups had significant increases in the incidence rate of renal involvement, rate of hormone application, and median length of hospital stay (P < 0.05), while there was no signifcant difference in course of disease before admission (P > 0.05). Conclusions Children with HSP have a low serum 25-(OH)D3 level, and such children may have a high risk of renal involvement, a high rate of hormone application, and a prolonged length of hospital stay. However, further studies are needed to investigate whether vitamin D supplementation is helpful to the treatment of HSP and can shorten the course of disease in children with HSP.
[1] 丁云峰, 李志辉, 吴天慧, 等. 儿童过敏性紫癜伴胰腺损害的临床特征[J]. 中华实用儿科临床杂志, 2013, 28(7):525-527.
[2] Iqbal SF, Freishtat RJ. Mechanism of action of vitamin D in the asthmatic lung[J]. J Investig Med, 2011, 59(8):1200-1202.
[3] Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides[J]. Ann Rheum Dis, 2006, 65(7):936-941.
[4] 中华医学会儿科学分会儿童保健学组, 《中华儿科杂志》编辑委员会. 儿童微量营养素缺乏防治建议[J]. 中华儿科杂志, 2010, 48(7):502-509.
[5] Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management:review of current knowledge and recommendations[J]. Pediatrics, 2008, 122(2):398-417.
[6] 胡亚美, 江载芳. 诸福棠实用儿科学(上册)[M]. 第7版. 北京:人民卫生出版社, 2005:688-690.
[7] 唐雪梅. 过敏性紫癜病因及免疫发病机制[J]. 实用儿科临床杂志, 2012, 27(21):1634-1636.
[8] 郭桂梅, 王娟, 夏敏, 等. 过敏性紫癜患儿血浆1,25(OH)2D3、维生素D受体和24-羟化酶表达的意义[J]. 中华实用儿科临床杂志, 2013, 28(21):1640-1642.
[9] Dimeloe S, Nanzer A, Ryanna K, et al. Regulatory T cells, inflammation and the allergic response-The role of glucocorticoids and vitamin D[J]. J Steroid Biochem Mol Biol, 2010, 120(2-3):86-95.
[10] Mahon BD, Wittke A, Weaver V, et al. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells[J]. J Cell Biochem, 2003, 89(5):922-932.
[11] 程雷, 吴海燕, 田慧琴. 维生素D在变应性鼻炎发病中的作用[J]. 临床耳鼻咽喉头颈外科杂志, 2016, 30(9):675-677.
[12] 吴秀萍. 小儿36例复发及慢性过敏性紫癜临床分析[J]. 中国全科医学, 2010, 13(9):999-1000.
[13] Donnithorne KJ, Atkinson TP, Hinze CH, et al. Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura[J]. J Pediatr, 2009, 155(1):136-139.
[14] Jauhola O, Ronkainen J, Koskimies O, et al. Renal manifestations of Henoch-Schönlein purpura in a 6-month prospective study of 223 children[J]. Arch Dis Child, 2010, 95(11):877-882.
[15] 徐祝菲, 刘恩梅, 邓昱. 血清维生素D水平与儿童支气管哮喘的相关性及其可能机制[J]. 实用儿科临床杂志, 2012, 27(9):715-717.
[16] Li YC. Vitamin D receptor signaling in renal and cardiovascular protection[J]. Semin Nephrol, 2013, 33(5):433-447.
